Insurancenewsnet.com

“Testosterone Kit” in Patent Application Approval Process (USPTO 20160120712)

This patent application has not been assigned to a company or institution. The following quote was obtained by the news editors from the background information supplied by the inventors: "With the ...
Medscape

New Boxed Warning for Testosterone Gels to Protect Against Secondary Exposure

May 7, 2009 — The US Food and Drug Administration (FDA) held a press conference today to announce a change in the labeling of the testosterone gel products AndroGel 1% (Solvay Pharmaceuticals) and ...
Business Wire

Marius Pharmaceuticals Submits New Drug Application to U.S. FDA for Next-Generation Oral Testosterone Replacement Therapy in Male Patients With Hypogonadism

RALEIGH, N.C.--(BUSINESS WIRE)--Marius Pharmaceuticals, a specialty pharmaceutical company focusing on treating conditions that are primarily associated with testosterone deficiency, today announced ...
Business Wire

Transdermal Delivery Solutions Subsidiary, Hormone Replacement Technologies, Receives FDA Approval to Begin Pivotal Clinical Trials of Testagen® TDS for the Treatment of Low ...

PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Transdermal Delivery Solutions Corporation (TDSC) announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug ...
Healio

Serum testosterone levels vary throughout day following transdermal application

Please provide your email address to receive an email when new articles are posted on . In a randomized double blind, placebo-controlled trial with older men assigned either AndroGel 1% (transdermal ...
Healio

FDA calls for labeling changes, medication guides for two topical testosterone gels

Please provide your email address to receive an email when new articles are posted on . The U.S. Food and Drug Administration today announced that it is requiring manufacturers of two prescription ...
Tennessean

ARSYNL Rx Introduces First Needle-Free Testosterone HypoSpray® for Men and Women

ARSYNL Rx, a leader in provider-guided telehealth and modern hormone access, today announced the launch of its exclusive HypoSpray® transdermal testosterone option, the first spray-on testosterone ...